Business description

4SC is a Munich-based cancer biopharmaceutical company. Resminostat (HDAC inhibitor) is the lead candidate for cutaneous T-Cell lymphoma (pivotal study started in Q416). It has a second compound, 4SC-202 (Phase II) and a preclinical asset, 4SC-208. 4SC also has several partners including Yakult Honsha for resminostat in Japan.

Stock data

Market cap.€254.4m
Last close€8.30
High / Low (52 weeks)€8.5 / €2.3
Stock market listingDE
Forecast net cash (€m)36.5
Forecast gearing ratio (%)N/A
SectorPharmaceutical & healthcare

Price performance

Relative *(1.2)69.8217.7

* % Relative to local index

Other companies in sector Show

aap Implantate Aastrom Biosciences
AB Science Abcam
Abivax SA Ablynx
Abzena Acarix
Achillion Pharmaceuticals Acorda Therapeutics
Actinium Pharmaceuticals Active Biotech
Acucela Addex Therapeutics
Adherium Advanced Medical Solutions
Aegerion Pharmaceuticals Aeterna Zentaris
AFT Pharmaceuticals Agennix
Akari Therapeutics Alchemia
Alexza Pharmaceuticals Algeta
Alimera Sciences ALK Abello
Alkermes Allergy Therapeutics
Alliance Pharma Allium Medical Solutions
Alnylam Pharmaceuticals Amarantus BioScience
Amarin Amplifon
AmpliPhi Biosciences Angle
Animalcare Group Anteo Diagnostics
Anthera Pharmaceuticals Aratana Therapeutics
Ardea Biosciences Ardelyx
Arena Pharmaceuticals arGEN-X
Argos Therapeutics Ariad Pharmaceuticals
Arix Bioscience Ark Therapeutics Group
ArQule Array BioPharma
Arrowhead Research Corporation Ascendis Pharma
ASIT biotech ASLAN Pharmaceuticals
Astex Pharmaceuticals Athersys
Atossa Genetics Avacta Group
Avalanche Biotechnologies AVEO Pharmaceuticals
Avita Medical Balda
Basilea Pharmaceutica Bavarian Nordic
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLight Life Sciences BioLineRx
BiondVax Pharmaceuticals Bionomics
Bionor Pharma Biota Holdings
Biotie Therapies Corp Biotron
Bluebird Bio Bone Therapeutics
Bonesupport BrainStorm Cell Therapeutics
BTG C4X Discovery Holdings
Can-Fite BioPharma Cantargia
Capstone Therapeutics Carmat
CASI Pharmaceuticals Cell Therapy
Celldex Therapeutics Cellectis
Cellular Biomedicine Group Celyad
Cerulean Pharma Circadian Technologies
Clal Biotechnology Industries Clavis Pharma
Cleveland BioLabs Clinigen Group
Clinuvel CO.DON
CollPlant Holdings Consort Medical
Corium International Crescendo
Crossject CSL
Curetis NV Curis
Cytori Therapeutics Cytos Biotechnology
CytRx Corporation DBV Technologies
Dechra Pharmaceuticals Delcath Systems
Deltex Medical Derma Sciences
DiaSorin Diaxonhit
e-Therapeutics Egalet Corporation
EKF Diagnostics Elbit Medical
Emergent BioSolutions Endocyte
Epigenomics Erytech Pharma
Esperion Therapeutics Evotec
Exact Sciences Exelixis
EyeGate Pharmaceuticals Factor Therapeutics
Formycon Forward Pharma
Fresenius SE & Co. KGaA Futura Medical
Galapagos Galmed Pharmaceuticals
Genedrive Genfit
Genkyotex Genmab
GeoVax GI Dynamics
Gilead Sciences GNI Group Ltd
GW Pharmaceuticals Halozyme Therapeutics
Heat Biologics Inc. Heidelberg Pharma
Horizon Discovery Hutchison China MediTech
Hybrigenics iCo Therapeutics
Idenix Immune Pharmaceuticals
Immunicum Immunodiagnostic Systems Holdings
Immunovia ImmuPharma
Immutep Imprimis Pharmaceuticals
Imugene Incyte Corporation
Infinity Pharmaceuticals Innate Pharma
Insmed Intec Pharma
International Stem Cell Invion
Ion Beam Applications Ipsogen
Iridex Ironwood Pharmaceuticals
Islet Sciences Ixico
Japan Tobacco KaloBios Pharmaceuticals
Kane Biotech Karolinska Development
Kazia Therapeutics Keryx Biopharmaceuticals
Kiadis Pharma Laboratorios Farmacéuticos ROVI
LCA-Vision LeMaitre Vascular
Lifeline Scientific LifeWatch
Ligand Pharmaceuticals Lipocine
Lombard Medical Technologies MagForce
Mast Therapeutics Medcom Tech
Medicago MediciNova
Medigene Medivir
Merrimack Pharmaceuticals Merrion Pharmaceuticals
Mesoblast MethylGene
MGC Pharmaceuticals Midatech Pharma
MISSION Therapeutics Molecular Partners
MolMed Mologen
Momenta Pharmaceuticals MorphoSys
Nanobiotix Nanosonics
Navidea Biopharmaceuticals Nektar Therapeutics
NeoStem Neovacs
NetScientific NeuroVive Pharmaceutical
Newron Pharmaceuticals Nexstim
NicOx NMC Health
NorDiag Nordion
NovaBay Pharmaceuticals Novacyt
NPS Pharmaceuticals Nuevolution
Ocata Therapeutics Omega Diagnostics Group
Omeros Corporation OncoGenex Pharmaceuticals
Oncology Venture Oncolytics Biotech Inc
OncoMed Pharmaceuticals Onconova Therapeutics
Oncothyreon Onxeo
Onyx Pharmaceuticals Opexa Therapeutics
OPMEDIC Group Optos
Orexigen Therapeutics Orexo
Orgenesis Oryzon Genomics
Ossur OvaScience
OWL Oxford BioMedica
Pacific Edge Paion
Paladin Labs Patheon
PDL BioPharma Pharmacyclics
PharmaMar Pharmaxis
Pharming Group Photocure
Phylogica Pixium Vision
Pluristem Therapeutics Prescient Therapeutics
Probiodrug ProMetic Life Sciences
Prosensa Proteome Sciences
PsiOxus QRxPharma
Quantum Genomics Quantum Pharmaceuticals
Race Oncology RedHill Biopharma
Regeneus Relmada Therapeutics
ReNeuron Group Resverlogix
REVA Medical Rovi
RXi Pharmaceuticals Sangamo BioSciences
Sarepta Therapeutics Sartorius
Scancell Selvita
Shire Sierra Oncology
Silence Therapeutics Simavita
Sinclair Pharma Sirtex Medical
Skyepharma Smith & Nephew
Sobi Sosei Group Corporation
Source Bioscience SQI Diagnostics
Stallergenes StemCells
Stentys Stratec Biomedical
Sucampo Pharmaceuticals Sunesis Pharmaceuticals
Surgical Innovations Sygnis
SymBio Pharmaceuticals Synairgen
Synergy Health Synta Pharmaceuticals
T‐cell cancer therapies Targovax
TearLab Corp Tekmira
Telix Pharmaceuticals TESARO
Theraclion Therapix Biosciences
Threshold Pharmaceuticals ThromboGenics
TiGenix Tissue Regenix
Tissue Therapies Titan Pharmaceuticals
Tonix Pharmaceuticals Topotarget
Touchstone Innovations Transgene
Trillium Therapeutics Trimel Pharmaceuticals
TruScreen Ltd TxCell
UCB UDG Healthcare
uniQure NV Universal Biosensors
VBI Vaccines Vectura
Verastem Verisante Technology
Vernalis Verona Pharma
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus VolitionRx
WaferGen Biosystems Xbrane Biopharma
Xencor Zafgen
Zealand Pharma Ziopharm Oncology

Company news

4SC AG raises €41m

Sun, 09 Jul 2017 16:41:15 GMT

4SC Signs Licensing and Development Agreement with Menarini for Resminostat in ...

Thu, 16 Apr 2015 11:51:34 GMT

Wellington Partners backs German biotech company 4SC AG

Wed, 08 Jul 2015 14:53:08 GMT

4SC and Yakult Honsha Announce Exclusive License Agreement for Japan for the ...

Thu, 14 Apr 2011 06:56:15 GMT

Global Nuclear Receptor ROR-Gamma Market 2018 4SC AG, Advinus Therapeutics Ltd ...

Fri, 16 Mar 2018 06:14:02 GMT

Investment summary

The equity capital raise (€41m gross) in July will fund 4SC's progressive R&D plan. Its pivotal 150-patient study with anti-cancer compound resminostat (broad spectrum-HDAC inhibitor) for CTCL has recruited more than one third of patients. Top-line data is expected in H119. Resminostat has also been licensed to Yakult Honsha in Japan, which is preparing for Phase II in biliary tract cancer based on positive data from a Phase I trial. Alongside resminostat, 4SC is currently evaluating the combination of 4SC-202 with a checkpoint inhibitor in a Phase Ib/II trial in melanoma. 4SC intends to advance 4SC-202 into a first pivotal study (early 2019) and complete formal development of 4SC-208 with the aim of starting Phase I early 2019. Other ongoing positives include a partnership with Link Health in China for its oncology Eg5 inhibitor, 4SC-205, a worldwide license for 4SC’s preclinical inhibitors of the Kv1.3 ion channel, and receipt of a milestone payment from Immunic for the sale of 4SC’s immunology portfolio in September 2016.

Last updated on 02/03/2018

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2015A 3.3 (7.9) (8.4) (58.58) N/A N/A
2016A 2.1 (10.9) (10.9) (54.17) N/A N/A
2017E 3.4 (12.7) (12.8) (48.70) N/A N/A
2018E 2.7 (16.2) (16.3) (50.99) N/A N/A

Last updated on 16/02/2018

Latest video

Executive interview - 4SC

Industry outlook

Resminostat could become the first HDAC inhibitor to gain EU approval for CTCL (vs two HDACs approved in the US), but more importantly the maintenance treatment indication would be unique, potentially offering a competitive edge in Europe and the US.

Last updated on 02/03/2018

Key management

Jason Loveridge, CEO
Dr. Anna Niedl , Manager Corporate Communications and Investor

Company address

Am Klopferspitz 19a
+49 (0)89 700763-0
View website